IRF1 and central nervous system cancer: MR1 high-expressing gliomas showed upregulation in IRF1 for grade II (P < .0001), III (P < .0001), IV (P < .05), and combined (P < .0001); IRF2 for grade II (P < .0001), III (P < .0001), IV (P < .0001), and combined (P < .0001); CEPBP for grade III (P < .0135) and combined (P < .0001); and PRDM1 for grade II (P < .0001), III (P < .0001), IV (P < .0235), and combined (P < .0001; Figure 6A).